
Alzheimer’s disease is often broadly referred to as “Type 3 diabetes,” because it’s thought that glucose processing goes haywire in the neurodegenerative disease, just as it does in diabetes.
A new National Institutes of Health study adds some credence to that theory, finding that glitches in the way the brain breaks down glucose — a process called glycolysis — seem to correspond with more severe symptoms in patients with Alzheimer’s.
What is it?
STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- STAT+ Conversations
- Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
Diabetes and Alzheimer’s disease: Can tea phytochemicals play a role in prevention? https://goo.gl/Aq8GDG. Here’s a study done by us on the above topic.